

# Liquid-Based Pap Technologies Have Substantially Different FDA Claims



	<i>ThinPrep</i> ®	<i>SurePath</i> ®	<i>MonoPrep</i> ™
Year of Original FDA Approval	1996	1999	2005
Replacement for Conventional Pap	√	√	√
Improved Specimen Quality	√	√	√
Improved HSIL Detection <sup>1</sup>	√	√	*
Significantly More Effective than CP	√	*	*
Glandular Disease Detection <sup>2-7</sup>	√	*	*
Approved for Adjunctive HPV Testing	√	*	*
Approved for Adjunctive CT/NG Testing	√	*	*

\* What are the implications/liabilities of off-label testing?

Información tomada de [www.medipath.net](http://www.medipath.net)

1. Versus the conventional pap smear. Cytyc Corporation. The ThinPrep Pap Test Package Insert results based on a multi-site prospective, historically controlled, direct-to-vial study of routine screening and referral patient populations at 10 leading academic institutions resulting in a 59.7% increase in the detection of HSIL+ lesions for ThinPrep specimens. 2. Ashfaq R, Gibbons D, Vela C, Saboorian MH, Iliya F. ThinPrep Pap Test. Accuracy for glandular disease. Acta Cytol 1999; 43: 81-5. 3. Bai H, Sung CJ, Steinhoff MM: ThinPrep Pap Test promotes detection of glandular lesions of the endocervix. Diagn Cytopathol 2000;23:19-22. 4. Carpenter AB, Davey DD: ThinPrep Pap Test: Performance and biopsy follow-up un a university hospital. Cancer Cytopathology 1999; 87: 105-12. 5. Guidos BJ, Selvaggi SM. Detection of endometrial adenocarcinoma with the ThinPrep Pap test. Diagn Cytopathol 2000; 23: 260-265. 6. Schorge JO, Hossein Saboorian M, Hynan L, Ashfaq R. ThinPrep detection of cervical and endometrial adenocarcinoma: A retrospective cohort study. Cancer Cytopathology 2002; 96: 338-43. 7. Wang N, Emancipator SN, Rose P, Rodriguez M, Abdul-Karim FW. Histologic follow-up of atypical endocervical cells. Liquid-based, thin-layer preparation vs. conventional Pap smear. Acta Cytol 2002; 46: 453-457.